

EINSTEIN et al.  
Appl. No. 10/560,723  
Atty. Ref.: 3665-166  
Amendment After Final rejection  
April 28, 2008

**AMENDMENTS TO THE CLAIMS:**

Amend the claims as follows:

1. (Currently Amended) An isolated nucleic acid that is expressed by human prostate cancer cells, wherein said nucleic acid comprises selected from the group consisting of:

- (i) the nucleic acid comprising the sequence of SEQ ID NO: 92;
- (ii) variants thereof, wherein such variants have a nucleic acid sequence that is at least 95% identical to the sequence of (i) when aligned without allowing for gaps;  
and
- (iii) fragments of (i) or (ii) having a size of at least 20 nucleotides in length, wherein said fragments comprise a portion of the sequence of (i) or (ii) comprising an exon-exon, exon-intron or intron-intron junction sequence generated by splicing.

2. (Currently Amended) [[The]] A nucleic acid of Claim 1, which comprises at least a fragment of SEQ ID NO:92 encoding SEQ ID NO:183 the nucleic acid sequence of SEQ ID NO-92.

Claim 3. (Canceled)

Claims 4-15. (Canceled)

16. (Currently Amended) A diagnostic kit for detection of prostate cancer which comprises a nucleic acid according to Claim 1 or 2 and a detectable label.

EINSTEIN et al.  
Appl. No. 10/560,723  
Atty. Ref.: 3665-166  
Amendment After Final rejection  
April 28, 2008

Claim 17. (Canceled)

Claims 18-31. (Canceled)

Claims 32-33. (Canceled)

Claim 34. (Canceled)